It's a total "rookie" mistake by a kid that was still in college when the market made its low in March of 2009.
It's one thing to claim to be a value investor and use the methodology of Benjamin Graham and David Dodd. It's entirely another to make short bets against the likes of a TSLA, NFLX, or even EXAS.
Travis seems very confused.
You clowns are getting more and more desperate by the day.
Either that, or you are a kid playing on the Internet at 5am in the morning East Coast time.
When is school back in session?
One only has to go check out Travis' twitter account to see where he has lost a ton of money.... TSLA, NFLX, and EXAS.
He's not just obsessed with Kevin Conroy.
Try Elon Musk and Reed Hasting's too.
An "old" article with DRAMATIC FUTURE IMPACT on the addressable screening population.
The study was published in a News article on the MD Anderson website from Nov. 5th, 2014.
I am having great difficulty posting the second half of it for some reason...
"Over the next 15 years, more than 1 in 10 colon cancers and nearly 1 in 4 rectal cancers will be diagnosed in patients YOUNGER than the traditional screening age, according to researchers at MD Anderson."
This growing public health problem is underscored by data trends among 20 - 34 years olds in the US., among whom the incidence of colon and rectal cancer is expected to increase by 90% and 124.2%, respectively, by 2030."
Published in the current issue of JAMA Surgery, the findings build on prior studies of CRC trends but go a step further by providing quantitative estimates of exponentially increasing risk for CRC among patients who fall under 50, the age at which CRC screening becomes recommended for the general public. The authors point to lifestyle and behavioral factors such as obesity, lack of physical activity and a Western diet as major risk factors for CRC, though the exact causes of the predicted increases are not known.
“This is an important moment in cancer prevention,” said principal investigator George J. Chang, MD, MS, associate professor, Departments of Surgical Oncology and Health Services Research. “We’re observing the potential real impact of CRC among young people if no changes are made in public education and prevention efforts. This is the moment to reverse this alarming trend.”
See how easy it was to answer your question Farrker?
Now why couldn't your boy BioPiggy tell us what floor the Exact reception was on?
I don't know of another medical diagnostics company that enjoys a similar situation, in which 45% of the addressable market is ALREADY reimbursed at $493 per test at commercial launch.
I was at the EXAS reception the night before Investor Day.
It was held on a rooftop terrace across the street from the Madison State Capitol.
Great atmosphere and opportunity to meet members of Team EXACT as well as a few buy-side and sell-side analysts from the Street.
You are mistaken.
The Company does not issue management and the BOD "cheaper" stock after an offering.
The shares that the BoD acquired recently are Restricted Stock Units (RSU) that were issued pursuant to the Company's non-employee director compensation policy. The price is "0".
For employees like Lidgard, Arora, Meaghan, and Conroy they were issued not only RSU's but (in Lidgard's case) also obtained some shares purchased trough an Employee Stock Purchase Plan.
If anything, the recent secondary offering HURT them because their automatic 10b5-1 sales to cover their tax liability occurred at a price of 24.04
Just to be perfectly clear here....
There were NO INSIDER SALES per se.
Only shares "surrendered" to pay for tax liability.
Tests like PanC and Esophageal were never really going to be developed as average risk population screening risks. They are starting out as diagnostic in nature, for high risk populations. They might even be an LDT, which could save some time with the FDA approval process.
Part of this is just the biological nature of where the Pancreas and Esophagus is, given that any kind of DNA from these two areas winds up getting highly "degraded" as it makes its way through the stomach and digestive tract.
At some point, they might be able to turn these tests from diagnostic to screening. No one has ever claimed that they would only be developed for screening. That is a total misrepresentation from BioPiggy.
You guys need to start doing your own homework.
Watch the Investor Day presentation by Dr. Ahlquist and stop listening to a short seller like BioPigg who I might add... completely disappeared from this board as the stock surged up to 32.85
Instead of asking BioPiggy, why not ask someone that was actually at last year's Annual Shareholder Meeting (like myself) who heard KC talk about how they had 41 studies currently ongoing with Mayo, and how at some point they would decide which one's had the most realistic potential, and how they weren't sure whether they would be either a "screening" test, or more of a "diagnostic" test?
BioPigg is a fraud.
He was never at last year's shareholder meeting or this year's shareholder meeting.
And he certainly wasn't at this year's reception the night before Investor Day, given how he said that the reception was held at the State House where the Wisconsin Chamber Orchestra played. As "Scorekeeper" pointed out, there was NO RECEPTION at the State House.
Why do I know this???
Because I was at the reception.
I was able to meet various member's of Team Exact along with several analysts from both the Buy side and Sell side.
Yup....Crickets is right!
I will bet anyone here $100 that BioPiggy evades this question like the Plague.
He will never answer it.
Its pretty clear that he's lying about being at the reception.
Otherwise, why not just name the name of the building that it was held in and what floor the reception took place on?